87 terminated. 87 Phase 2, 10 Phase 3, 5 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 87 | Terminated 87 |
| Phase 3 | 10 | Terminated 10 |
| Phase 1 | 5 | Terminated 5 |
Follow Tauopathies: new trials by email Literature Review of Tauopathies trials Research Report on Tauopathies
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Extension Study of Participants From SPG302-ALZ-101 SPG302 - Alzheimer's Disease | Phase 2 | Terminated | Spinogenix | 12 | 2025-03-25 | 2025-12-18 |
| A Study to Evaluate the Efficacy and Safety of MK-1167 in Participants With Alzheimer's Disease Dementia (MK-1167-008) MK-1167, Placebo - Alzheimer Disease, Dementia | Phase 2 | Terminated | Merck Sharp & Dohme LLC | 369 | 2024-12-16 | 2026-07-01 |
| Study of ASN51 in Adults With Early Alzheimer's Disease ASN51, Placebo - Alzheimer Disease | Phase 2 | Terminated | Asceneuron S.A. | 123 | 2024-10-16 | 2025-06-29 |
| Ultrasonic Neuromodulation for Treatment of Cognitive Impairment Diadem prototype - Alzheimer Disease, Dementia | Phase 1 / Phase 2 | Terminated | University of Utah | 1 | 2024-08-18 | 2025-05-25 |
| Safety and Pharmacodynamics of SHR-1707 in Alzheimer's Disease Patients SHR-1707, SHR-1707 placebo - Alzheimer's Disease | Phase 2 | Terminated | Shanghai Hengrui Pharmaceutical Co., Ltd. | 46 | 2024-02-05 | 2026-05-13 |
| A Phase 2, Randomized, Prospective Double-Blind, Single-Center, Placebo-controlled Study to Evaluate Safety, Tolerability, Target Engagement, and Efficacy of PrimeC in Patients With Mild to Moderate Alzheimer's Disease. PrimeC, Placebo - Alzheimer Disease | Phase 2 | Terminated | NeuroSense Therapeutics Ltd. | 8 | 2023-11-19 | 2026-04-09 |
| Efficacy and Safety of GSK4527226 [AL101] in Participants With Early Alzheimer's Disease GSK4527226, Placebo - Alzheimer's Disease | Phase 2 | Terminated | GlaxoSmithKline | 367 | 2023-10-20 | 2026-09-17 |
| An Open-Label Extension of XPro1595 in Patients With Alzheimer's Disease XPro1595 - Alzheimer Disease, Dementia | Phase 2 | Terminated | Inmune Bio, Inc. | 11 | 2023-02-21 | 2026-02-27 |
| A Long-term Extension Study to Evaluate Safety, Tolerability, and Efficacy of AL002 in Alzheimer's Disease AL002 - Alzheimer's Disease | Phase 2 | Terminated | Alector Inc. | 197 | 2023-01-04 | 2026-02-25 |
| Efficacy and Safety of MK-1942 as an Adjunct Therapy in Participants With Mild to Moderate Alzheimer's Disease Dementia (MK-1942-008) MK-1942, Placebo - Alzheimer's Disease | Phase 2 | Terminated | Merck Sharp & Dohme LLC | 99 | 2022-12-02 | 2024-12-10 |
| Efficacy and Safety of Wei Li Bai Capsules in the Treatment of Alzheimer's Disease Wei Li Bai capsules, Placebo Comparator of Wei Li Bai capsules - Alzheimer Disease | Phase 2 | Terminated | Capital Medical University | 105 | 2022-10-01 | 2024-12-04 |
| A Long Term Extension Study to Assess the Safety of TB006 in Participants With Alzheimer's Disease TB006 - Alzheimer's Disease | Phase 2 | Terminated | TrueBinding, Inc. | 119 | 2022-09-15 | 2026-05-06 |
| Piromelatine 20 mg in Participants With Mild Dementia Due to Alzheimer's Disease Piromelatine 20 mg, Placebo - Alzheimer's Disease | Phase 2 / Phase 3 | Terminated | Neurim Pharmaceuticals Ltd. | 216 | 2022-06-15 | 2026-09-09 |
| A Phase 2a Study to Investigate REM0046127 in Mild to Moderate Alzheimer's Disease REM0046127 High Dose, REM0046127 Low Dose, Placebo - Alzheimer Disease | Phase 2 | Terminated | reMYND | 14 | 2022-06-07 | 2025-12-03 |
| Open-Label Extension of the PTI-125-04 Study in Mild-to-Moderate Alzheimer's Disease simufilam - Alzheimer's Disease | Phase 2 | Terminated | Cassava Sciences, Inc. | 90 | 2022-05-12 | 2025-08-15 |
| A Trial to Evaluate the Efficacy and Safety of PQ912 in Patients With Early AD PQ912, Placebo - Alzheimer Disease | Phase 2 | Terminated | Vivoryon Therapeutics N.V. | 112 | 2021-11-15 | 2025-12-12 |
| A Study of the Effects of CY6463 in Participants With Alzheimer's Disease With Vascular Pathology CY6463, Placebo - Alzheimer's Disease With Vascular Pathology | Phase 2 | Terminated | Tisento Therapeutics | 12 | 2021-11-02 | 2024-10-30 |
| Study of the Efficacy and Safety of Various Anti-inflammatory Agents in Participants With Mild Cognitive Impairment or Mild Alzheimer's Disease Canakinumab, Placebo - Mild Cognitive Impairment, Alzheimer Disease | Phase 2 | Terminated | Novartis Pharmaceuticals | 34 | 2021-10-28 | 2025-10-16 |
| Open Label Study of ATH-1017 for Treatment of Mild to Moderate Alzheimer's Disease ATH-1017 - Alzheimer Disease | Phase 2 / Phase 3 | Terminated | LeonaBio | 423 | 2021-06-30 | 2025-04-01 |
| A Study of JNJ-63733657 in Participants With Early Alzheimer's Disease JNJ-63733657, Placebo - Alzheimer Disease, Cognitive Dysfunction | Phase 2 | Terminated | Janssen Research & Development, LLC | 523 | 2021-01-06 | 2026-04-03 |
Showing 20 of 87. Sign in to see all of them.
Alzheimer Disease (84) · Dementia (16) · Cognitive Dysfunction (10) · Brain Diseases (5) · Inflammation (4) · Mental Disorders (4) · Nervous System Diseases (4) · Central Nervous System Diseases (3) · Neurocognitive Disorders (3) · Neurodegenerative Diseases (3) · Supranuclear Palsy, Progressive (3) · Aggression (2) · Plaque, Amyloid (2) · Psychomotor Agitation (2)
Central Nervous System Diseases (84) · Neurodegenerative Diseases (84) · Nervous System Diseases (83) · Brain Diseases (82) · Neurocognitive Disorders (81) · Mental Disorders (80) · Dementia (68) · Pathological Conditions, Signs and Symptoms (11) · Cognition Disorders (9) · Neurologic Manifestations (6) · Signs and Symptoms (6) · Basal Ganglia Diseases (4) · Movement Disorders (4) · Pathologic Processes (4)
Donepezil (4) · pozanicline (3) · tilavonemab (3) · ABT-126 (2) · Umibecestat (2) · atabecestat (2) · bapineuzumab (2) · gantenerumab (2) · gosuranemab (2) · talsaclidine fumarate (2) · vanutide cridificar (2) · (18F)GTP1 (1) · 3-(5-chloro-2-furoyl)-3,7-diazabicyclo(3.3.0)octane (1) · 7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole (1) · BMS 708163 (1)
Merck Sharp & Dohme LLC (5) · Pfizer (5) · AbbVie (3) · Abbott (3) · Biogen (3) · Janssen Research & Development, LLC (3) · Novartis Pharmaceuticals (3) · AbbVie (prior sponsor, Abbott) (2) · AstraZeneca (2) · Boehringer Ingelheim (2) · Eli Lilly and Company (2) · Epix Pharmaceuticals, Inc. (2) · GlaxoSmithKline (2) · JANSSEN Alzheimer Immunotherapy Research & Development, LLC (2) · Aaron Ritter, MD (1)
United States (65) · Canada (25) · Spain (21) · United Kingdom (20) · Australia (18) · France (17) · Germany (16) · Italy (14) · Japan (14) · Netherlands (11) · Belgium (9) · South Korea (8) · Sweden (8) · Finland (7) · Poland (7)
Laura Gault, MD (2) · A Keegan, MD (1) · Aaron R Ritter, MD (1) · Alan J Lerner, MD (1) · Alan K Jacobs, MD (1)
PMID 40603145, PMID 25669746, PMID 25973909, PMID 26414022, PMID 26967214, PMID 27756421, PMID 27767991, PMID 27807285, PMID 27871675, PMID 29622037, PMID 29719179, PMID 29955661, PMID 30129411, PMID 31387606, PMID 31518224, PMID 31764959, PMID 32410694, PMID 33049114, PMID 33252075, PMID 33253354, PMID 33464300, PMID 33609476, PMID 33719017, PMID 34385707, PMID 34736158, PMID 35384522, PMID 35696185, PMID 35794343, PMID 36641609, PMID 36671553, PMID 37325545, PMID 38012285, PMID 38599894, PMID 38606196, PMID 38825840, PMID 39350369, PMID 39513754, PMID 39559869, PMID 39974075, PMID 40120616, PMID 40216220, PMID 40375477, PMID 40937833, PMID 41431125, PMID 42389794
2014 (4), 2016 (3), 2017 (3), 2015 (2), 2018 (2), 1UF1AG046150-01 (1), 2009 (1), 2023 (1), K23AG052633 (1), R01AG046179 (1), R01AG053267 (1), R01AG061146 (1), R21AT005510 (1), R56AG053267 (1), U01AG042791 (1)